Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Summary

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells

Conditions

• Ciliary Body and Choroid Melanoma, Medium/Large Size
• Ciliary Body and Choroid Melanoma, Small Size
• Extraocular Extension Melanoma
• Iris Melanoma
• Metastatic Intraocular Melanoma
• Mucosal Melanoma
• Recurrent Intraocular Melanoma
• Recurrent Melanoma
• Stage IIC Melanoma
• Stage IIIA Intraocular Melanoma
• Stage IIIA Melanoma
• Stage IIIB Intraocular Melanoma
• Stage IIIB Melanoma
• Stage IIIC Intraocular Melanoma
• Stage IIIC Melanoma
• Stage IV Intraocular Melanoma
• Stage IV Melanoma

Interventions

BIOLOGICAL

gp100 antigen

Given SC

BIOLOGICAL

tyrosinase peptide

Given SC

BIOLOGICAL

recombinant MAGE-3.1 antigen

Given SC

BIOLOGICAL

multi-epitope melanoma peptide vaccine

Given SC

BIOLOGICAL

incomplete Freund's adjuvant

Given SC

DRUG

Montanide ISA 51 VG

Given SC

DRUG

agatolimod sodium

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Southern California

  lead OTHER

Principal Investigators

• Jeffrey Weber · University of Southern California

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

16 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-05-31

Primary Completion

2007-09-30

Completion

2007-09-30

Countries

• United States

Study Locations